You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control
|
|---|---|
| Published in |
Cardiovascular Diabetology, September 2013
|
| DOI | 10.1186/1475-2840-12-129 |
| Pubmed ID | |
| Authors |
Martin Ridderstråle, Robbyna Svaerd, Cordula Zeller, Gabriel Kim, Hans J Woerle, Uli C Broedl |
| Abstract |
Sulfonylureas (SUs) are commonly used in the treatment of type 2 diabetes (T2DM), usually as second-line treatment after the failure of metformin. However, SUs are associated with poor durability, hypoglycemia and weight gain. Empagliflozin is a sodium glucose cotransporter 2 (SGLT2) inhibitor in development for the treatment of T2DM. In Phase II/III trials, empagliflozin reduced hyperglycemia, body weight and blood pressure, with a low incidence of hypoglycemia. The aim of this Phase III study is to compare the effects of empagliflozin and the SU glimepiride as second-line therapy in patients with T2DM inadequately controlled with metformin immediate release (IR) and diet/exercise. |
Mendeley readers
The data shown below were compiled from readership statistics for 241 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Denmark | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 239 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 46 | 19% |
| Student > Master | 29 | 12% |
| Researcher | 23 | 10% |
| Other | 20 | 8% |
| Student > Ph. D. Student | 18 | 7% |
| Other | 37 | 15% |
| Unknown | 68 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 81 | 34% |
| Nursing and Health Professions | 19 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 19 | 8% |
| Biochemistry, Genetics and Molecular Biology | 10 | 4% |
| Agricultural and Biological Sciences | 8 | 3% |
| Other | 25 | 10% |
| Unknown | 79 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 September 2013.
All research outputs
#20,656,161
of 25,373,627 outputs
Outputs from Cardiovascular Diabetology
#1,283
of 1,653 outputs
Outputs of similar age
#157,864
of 209,062 outputs
Outputs of similar age from Cardiovascular Diabetology
#11
of 19 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,653 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 209,062 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.